This study examines prevention and early detection of cervical cancer through self-administration screening of patients in Western Uganda. The cervix is the opening of the uterus or womb, which is the organ that supports babies before they are born. There are simple tests that let doctors know whether or not patients have cells that may become cancer. Some of the tests determine whether patients have an increased risk for cervical disease, but they do not actually confirm that they have it: these are called "screening" tests. This study may help researchers determine how to best deliver cervical cancer prevention services using the HPV test.
PRIMARY OBJECTIVES: I. To establish the acceptance and correlates of self-collected human papillomavirus (HPV)-ribonucleic acid (RNA) testing among women in the rural Ugandan community as well as the incidence and determinants of successful completion of the cervical cancer screening cascade from self-collected HPV testing to receipt of results. II. To ascertain the frequency and determinants of successful acquisition of treatment among women who have HPV detected on self-collected swabs in rural Uganda. III. To derive population-based estimates of the prevalence of high-risk HPV and cervical intraepithelial neoplasia (CIN) detected through community-based screening employing self-collected HPV RNA testing in rural Uganda. OUTLINE: Patients receive a specimen kit for collection of HPV samples. Patients complete questionnaire before and after collection HPV samples. Patients may also participate in an interview about general ideas in improving the screening and treatment process. Patients with positive results, undergo treatment for cervical cancer.
Study Type
OBSERVATIONAL
Enrollment
3,200
Undergo collection of cervical samples for HPV testing
Complete questionnaires
Makerere University College of Health Sciences School of Medicine
Kampala, Uganda
RECRUITINGNumber of participants who complete screening
The absolute number of participants successfully completing screening.
Time frame: 1 day
Proportion of women 25-49 years of age who complete screening
Overall proportions of women 25-49 years old successfully completing cervical cancer screening.
Time frame: 1 day
Proportion of participants who receive treatment after a positive screening result
Proportion of participants who receive treatment after screening positive for high-risk human papillomavirus (HPV) will be calculated with a 95% confidence interval.
Time frame: 6 months
Proportion of participants with positive, high-risk human papillomavirus (HPV)
Prevalence of participants with positive high-risk human papillomavirus (HPV)
Time frame: 1 day
Proportion of participants with cervical intraepithelial neoplasia (CIN2)+
Proportion of participants with cervical intraepithelial neoplasia (CIN2)+
Time frame: 1 day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.